Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795187

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795187

Tumor-Induced Osteomalacia

PUBLISHED:
PAGES: 281 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Tumor-Induced Osteomalacia Market to Reach US$129.5 Million by 2030

The global market for Tumor-Induced Osteomalacia estimated at US$114.5 Million in the year 2024, is expected to reach US$129.5 Million by 2030, growing at a CAGR of 2.1% over the analysis period 2024-2030. Drugs & Supplements Treatment, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$87.9 Million by the end of the analysis period. Growth in the Surgery Treatment segment is estimated at 1.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.2 Million While China is Forecast to Grow at 4.0% CAGR

The Tumor-Induced Osteomalacia market in the U.S. is estimated at US$31.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$24.3 Million by the year 2030 trailing a CAGR of 4.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Tumor-Induced Osteomalacia Market - Key Trends & Drivers Summarized

Why Is Tumor-Induced Osteomalacia a Unique Challenge in Endocrinology and Oncology?

Tumor-Induced Osteomalacia (TIO) is a rare disorder where tumors secrete excess FGF23, causing phosphate loss, weak bones, and chronic pain. Diagnosis is often delayed due to vague symptoms and the difficulty of locating small, slow-growing tumors responsible for the condition.

Once identified, surgical removal of the tumor usually resolves symptoms. However, inoperable or hidden tumors require long-term management with phosphate and vitamin D supplements, which are often insufficient for full recovery.

How Are Diagnostic Innovations and Targeted Therapies Changing TIO Management?

Imaging advances using somatostatin receptor-targeted tracers are improving tumor localization. Blood tests measuring FGF23 have become essential for diagnosing and tracking disease progression.

Burosumab, a monoclonal antibody that blocks FGF23, is a game-changing therapy for non-resectable cases. It restores phosphate levels, reduces pain, and improves mobility, offering targeted treatment where surgery is not an option.

The Growth in the Tumor-Induced Osteomalacia Market Is Driven by Several Factors…

Market growth is driven by improved diagnostics, awareness, and the emergence of biologics like burosumab. Rare disease research funding and policy incentives are increasing. Collaborative efforts among hospitals, research institutions, and pharmaceutical companies are bringing more attention and innovation to this neglected segment.

SCOPE OF STUDY:

The report analyzes the Tumor-Induced Osteomalacia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Drugs & Supplements Treatment, Surgery Treatment); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amgen Inc.
  • Amolyt Pharma
  • Ascendis Pharma A/S
  • Bayer AG
  • BridgeBio Pharma
  • Chugai Pharmaceutical Co., Ltd.
  • CRISPR Therapeutics
  • Debiopharm Group
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Radius Health, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Visterra, Inc. (Otsuka subsidiary)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38263

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Tumor-Induced Osteomalacia - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Improved Diagnostic Imaging Capabilities Propel Early Detection of TIO-Causing Tumors
    • Emergence of Targeted Therapies like Burosumab Strengthens Clinical Outcomes in Unresectable TIO
    • Increased Physician Awareness and Education Initiatives Accelerate Diagnosis and Treatment Uptake
    • Expansion of Orphan Drug Development Programs Spurs Innovation in Rare Bone Disorder Therapies
    • Advances in FGF23 Assay Technologies Drive Precision Monitoring and Treatment Personalization
    • Supportive Regulatory Frameworks for Ultra-Rare Diseases Generate Opportunities for Niche Biopharma Players
    • Rising Investment in Musculoskeletal Disease Research Throws the Spotlight on TIO as a Clinical Priority
    • Development of Cross-Specialty Diagnostic Pathways Enhances Case Identification Rates
    • Growth in Genetic and Molecular Diagnostic Tools Supports Earlier Intervention in TIO
    • Patient Advocacy and Access Programs Sustain Long-Term Treatment Adherence and Market Viability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tumor-Induced Osteomalacia Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tumor-Induced Osteomalacia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Drugs & Supplements Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Drugs & Supplements Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Drugs & Supplements Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Tumor-Induced Osteomalacia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Tumor-Induced Osteomalacia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Tumor-Induced Osteomalacia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!